重症肌无力

Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419-425.

• 全文
• 摘要

Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000 Jul;70(1):327-34.

• 摘要

Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010 Oct;23(5):530-5.

• 摘要

Benatar M. A systemic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006 Jul;16(7):459-67.

• 摘要

Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007 Oct 15;261(1-2):127-33.

• 摘要

Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009 Feb;102(2):97-107.

• 全文
• 摘要

Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016 Aug 11;375(6):511-22.

• 全文
• 摘要

Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;(2):CD002828.

• 全文
• 摘要

Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224.

• 全文
• 摘要

1.  Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419-425.

• 全文
• 摘要

2.  Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000 Jul;70(1):327-34.

• 摘要

3.  Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010 Oct;23(5):530-5.

• 摘要

4.  Tzartos JS, Zisimopoulou P, Rentzos M, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014 Feb;1(2):80-7.

• 全文
• 摘要

5.  Poulas K, Koutsouraki E, Kordas G, et al. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012 Sep 15;250(1-2):94-8.

• 摘要

6.  Rajakulendran S, Viegas S, Spillane J, et al. Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies. J Neurol. 2012 Dec;259(12):2736-9.

• 摘要

7.  Saulat B, Maertens P, Hamilton WJ, et al. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology. 2007 Aug 21;69(8):803-4.

• 摘要

8.  Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014 Mar 14;9(3):e91816.

• 全文
• 摘要

9.  Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014 Jun 3;82(22):1976-83.

• 摘要

10.  Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014 Aug;52:139-45.

• 摘要

11.  Yan M, Xing GL, Xiong WC, et al. Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. Ann N Y Acad Sci. 2018 Feb;1413(1):126-35.

• 摘要

12.  Zoltowska Katarzyna M, Belaya K, Leite M, et al. Collagen Q--a potential target for autoantibodies in myasthenia gravis. J Neurol Sci. 2015 Jan 15;348(1-2):241-4.

• 摘要

13.  Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018 Feb;1413(1):143-53.

• 摘要

14.  Berrih-Aknin S. Cortactin: a new target in autoimmune myositis and myasthenia gravis. Autoimmun Rev. 2014 Oct;13(10):1001-2.

• 摘要

15.  Cortés-Vicente E, Gallardo E, Martínez MÁ, et al. Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol. 2016 Sep 1;73(9):1099-104.

• 摘要

16.  Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014 Oct;13(10):1003-7.

• 摘要

17.  Labrador-Horrillo M, Martínez MA, Selva-O'Callaghan A, et al. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev. 2014 Oct;13(10):1008-12.

• 摘要

18.  Illa I, Cortés-Vicente E, Martínez MÁ, et al. Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci. 2018 Jan;1412(1):90-4.

• 摘要

19.  Drachman DB. Myasthenia gravis. N Engl J Med. 1994 Jun 23;330(25):1797-810.

• 摘要

20.  Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008 Jan;101(1):63-9.

• 摘要

21.  Tsonis AI, Zisimopoulou P, Lazaridis K, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study. J Neuroimmunol. 2015 Jul 15;284:10-7.

• 摘要

22.  Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011 Feb;69(2):418-22.

• 摘要

23.  Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol. 2012 Mar;259(3):427-35.

• 摘要

24.  Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012 Apr;69(4):445-51.

• 摘要

25.  Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec;1275:123-8.

• 摘要

26.  Tsivgoulis G, Dervenoulas G, Tzartos SJ, et al. Double seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies. Muscle Nerve. 2014 Jun;49(6):930-1.

• 摘要

27.  Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004;24:17-20.

• 摘要

28.  Andersen JB, Heldal AT, Engeland A, et al. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014;(198):26-31.

• 全文
• 摘要

29.  Santos E, Coutinho E, Moreira I, et al. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases. Muscle Nerve. 2016;54:413-421.

• 摘要

30.  Lee HS, Lee HS, Shin HY, et al. The epidemiology of myasthenia gravis in Korea. Yonsei Med J. 2016;57:419-425.

• 全文
• 摘要

31.  Breiner A, Widdifield J, Katzberg HD, et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016;26:41-46.

• 全文
• 摘要

32.  Peragallo JH, Bitrian E, Kupersmith MJ, et al. Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuroophthalmol. 2016;36:29-32.

• 摘要

33.  Engel AG, Sahashi K, Lambert EH, et al. The ultrastructural localization of the acetylcholine receptor, IgG and the third and ninth complement components at the motor end-plate and their implications for the pathogenesis of myasthenia gravis. In: Aguayo AJ, Karpati G, eds. Current topics in nerve and muscle research. Amsterdam: Excerpta Medica; 1979:111-22.

34.  Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012 Jul;8(5):427-38.

• 全文
• 摘要

35.  Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977 Jan 20;296(3):125-31.

• 摘要

36.  Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973 May 25;180(4088):871-2.

• 摘要

37.  Dau PC, Lindstrom JM, Cassel CK, et al. Plasmapheresis in myasthenia gravis and polymyositis. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston, MA: Houghton Mifflin; 1979:229-47.

38.  Hertel G, Mertens HG, Reuther P, et al. The treatment of myasthenia gravis with azathioprine. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston, MA: Houghton Mifflin; 1979:315-28.

39.  Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci. 2008;1132:180-92.

• 摘要

40.  Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015 Apr;72(4):396-404.

• 摘要

41.  Lisak RP, Barcellos L. New insights into the genetics of autoimmune myasthenia gravis: an evolving story. JAMA Neurol. 2015 Apr;72(4):386-7.

• 摘要

42.  Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Adv Neuroimmunol. 1994;4(4):373-86.

• 摘要

43.  Richards J, Howard JF Jr. Seronegative myasthenia gravis associated with malignant thymoma. Neuromuscul Disord. 2017 May;27(5):417-8.

• 摘要

44.  Guptill JT, Soni M, Meriggioli MN, et al. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016 Jan;13(1):118-31.

• 摘要

45.  Vander Heiden JA, Stathopoulos P, Zhou JQ, et al. Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing. J Immunol. 2017 Feb 15;198(4):1460-73.

• 全文
• 摘要

46.  Koneczny I, Stevens JA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2017 Feb;77:104-15.

• 全文
• 摘要

47.  Yi JS, Guptill JT, Stathopoulos P, et al. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018 Feb;57(2):172-84.

• 摘要

48.  Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May;8(5):475-90.

• 全文
• 摘要

49.  Simpson JA. Myasthenia gravis as an autoimmune disease: clinical aspects. Ann N Y Acad Sci. 1966 Jan 26;135(1):506-16.

• 摘要

50.  Salvado M, Canela M, Ponseti JM, et al. Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort. J Neurol Sci. 2016 Jan 15;360:110-4.

• 摘要

51.  Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 2004 Feb;5(2):183-8.

• 全文
• 摘要

52.  Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001 Mar;7(3):365-8.

• 摘要

53.  Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013 Dec;123(12):5190-202.

• 全文
• 摘要

54.  Yan M, Liu Z, Fei E, et al. Induction of anti-agrin antibodies causes myasthenia gravis in mice. Neuroscience. 2018 Mar 1;373:113-21.

• 摘要

55.  Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 Sep 12;89(11):1127-34.

• 摘要

56.  Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010 May 4;74(18):1434-40.

• 摘要

57.  Burns TM, Grouse CK, Conaway MR, et al; MG Composite and MG-QOL15 Study Group. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010 Feb;41(2):219-26.

• 摘要

58.  Benatar M. A systemic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006 Jul;16(7):459-67.

• 摘要

59.  Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003 Oct;126(Pt 10):2304-11.

• 全文
• 摘要

60.  Zouvelou V, Zisimopoulou P, Rentzos M, et al. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. Neuromuscul Disord. 2013 Jul;23(7):568-70.

• 摘要

61.  Rodriguez Cruz PM, Huda S, López-Ruiz P, et al. Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol. 2015 Aug;270:66-71.

• 摘要

62.  Skeie GO, Mygland A, Aarli JA, et al. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity. 1995;20(2):99-104.

• 摘要

63.  Choi Decroos E, Hobson-Webb LD, Juel VC, et al. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve. 2014 Jan;49(1):30-4.

• 摘要

64.  Abraham A, Alabdali M, Alsulaiman A, et al. Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle Nerve. 2017 Feb;55(2):166-70.

• 摘要

65.  Bou Ali H, Salort-Campana E, Grapperon AM, et al. New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle Nerve. 2017 Apr;55(4):532-38.

• 摘要

66.  Priola AM, Priola SM, Giraudo MT, et al. Chemical-shift and diffusion-weighted magnetic resonance imaging of thymus in myasthenia gravis: usefulness of quantitative assessment. Invest Radiol. 2015 Apr;50(4):228-38.

• 摘要

67.  Priola AM, Priola SM, Gned D, et al. Comparison of CT and chemical-shift MRI for differentiating thymoma from non-thymomatous conditions in myasthenia gravis: value of qualitative and quantitative assessment. Clin Radiol. 2016 Mar;71(3):e157-69.

• 摘要

68.  Liu WW, Chen A. Diagnosing myasthenia gravis with an ice pack. N Engl J Med. 2016 Nov 10;375(19):e39.

• 全文
• 摘要

69.  Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007 Oct 15;261(1-2):127-33.

• 摘要

70.  Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009 Feb;102(2):97-107.

• 全文
• 摘要

71.  de Meel RH, Lipka AF, van Zwet EW, et al. Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol. 2015 May 15;282:123-5.

• 摘要

72.  Shoffner JM, Shoubridge EA. Oxidative phosphorylation diseases of muscle. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of voluntary muscle. 7th ed. Cambridge, UK: Cambridge University Press; 2001:580-603.

73.  Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998 Feb;18(2):164-7.

• 摘要

74.  Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014;(10):CD006986.

• 全文
• 摘要

75.  Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;(12):CD005081.

• 全文
• 摘要

76.  Yeh JH, Chen HJ, Chen YK, et al. Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology. 2014 Sep 16;83(12):1075-9.

• 摘要

77.  Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016 Aug 11;375(6):511-22.

• 全文
• 摘要

78.  Keijzers M, de Baets M, Hochstenbag M, et al. Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes. Eur J Cardiothorac Surg. 2015 Jul;48(1):40-5.

• 摘要

79.  Goldstein SD, Culbertson NT, Garrett D, et al. Thymectomy for myasthenia gravis in children: a comparison of open and thoracoscopic approaches. J Pediatr Surg. 2015 Jan;50(1):92-7.

• 摘要

80.  Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;(2):CD002828.

• 全文
• 摘要

81.  Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998 Jun;50(6):1778-83.

• 摘要

82.  Drachman DB. Present and future treatment of myasthenia gravis. N Engl J Med. 1987 Mar 19;316(12):743-5.

• 摘要

83.  Witte AS, Cornblath DR, Schatz NJ, et al. Monitoring azathioprine therapy in myasthenia gravis. Neurology. 1986 Nov;36(11):1533-4.

• 摘要

84.  Heatwole C, Ciafaloni E. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1203-9.

• 全文
• 摘要

85.  Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010 May;41(5):593-8.

• 摘要

86.  Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008 Aug 5;71(6):400-6.

• 摘要

87.  Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224.

• 全文
• 摘要

88.  Yoshikawa H, Kiuchi T, Saida T, et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):970-7.

• 摘要

89.  Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Jul 12;55(1):7-15.

• 全文
• 摘要

90.  Barnett C, Katzberg HD, Keshavjee S, et al. Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. Orphanet J Rare Dis. 2014 Dec 24;9:214.

• 全文
• 摘要

91.  Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 Dec;16(12):976-86.

• 摘要

92.  Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;(12):CD002277.

• 全文
• 摘要

93.  Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011 Jun 7;76(23):2017-23.

• 摘要

94.  Köhler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher. 2011 Dec;26(6):347-55.

• 摘要

95.  Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008 Sep;15(9):893-908.

• 全文
• 摘要

96.  Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007 Apr;21(2 suppl 1):S57-107.

• 摘要

97.  Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011 Jan;1(1):16-22.

• 全文
• 摘要

98.  Sathasivam S. Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag. 2011;7:313-23.

• 全文
• 摘要

99.  Ponseti JM, Gamez J, Azem J, et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254-63.

• 摘要

100.  Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007 Mar 13;68(11):837-41.

• 摘要

101.  Hellmann MA, Mosberg-Galili R, Lotan I, et al. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014 Mar 15;338(1-2):39-42.

• 摘要

102.  Dalakas MC. IVIg in the chronic management of myasthenia gravis: is it enough for your money? J Neurol Sci. 2014 Mar 15;338(1-2):1-2.

• 摘要

103.  De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002 Jul;26(1):31-6.

• 摘要

104.  Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-14.

• 全文
• 摘要

105.  Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011 Sep;4(5):259-66.

• 全文
• 摘要

106.  Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):428-35.

• 摘要

107.  Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017 Sep 5;89(10):1069-77.

• 摘要

108.  Gamez J, Salvado M, Casellas M, et al. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017 Dec 15;383:118-22.

• 摘要

109.  Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(suppl 1):S30-8.

• 摘要

110.  Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004 Jul;41(Pt 4):294-302.

• 摘要

111.  Pasnoor M, He J, Herbelin L, et al. Phase II trial of methotrexate in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec;1275:23-8.

• 摘要

112.  Neuromuscular disease: Methotrexate has no steroid-sparing effect in patients with generalized myasthenia gravis. Nat Rev Neurol. 2016 Aug;12(8):430.

• 摘要

113.  Drachman DB. Comment: methotrexate for patients with generalized myasthenia gravis. Neurology. 2016 Jul 5;87(1):63.

• 摘要

114.  Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016 Jul 5;87(1):57-64.

• 摘要

115.  Ragheb S, Lisak R, Lewis R, et al. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol. 2008 Oct;65(10):1358-62.

• 全文
• 摘要

116.  Kim JY, Yang Y, Moon JS, et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol. 2008 Aug 13;199(1-2):151-4.

• 摘要

117.  Thangarajh M, Masterman T, Helgeland L, et al. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol.2006 Sep;178(1-2):161-6.

• 摘要

118.  Rowin J, Meriggioli MN, Tuzun E, et al. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28;63(12):2390-2.

• 摘要

119.  Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006 Nov;116(11):2843-54.

• 摘要

120.  Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76-84.

• 摘要

121.  Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016 Jun 1;73(6):652-8.

• 摘要

122.  Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015 Jan;22(1):17-23.

• 全文
• 摘要

123.  Hansen JS, Danielsen DH, Somnier FE, et al. Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve. 2016 Jan;53(1):73-7.

• 摘要

124.  Ducci RD, Lorenzoni PJ, Kay CS, et al. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord. 2017 Apr;27(4):352-57.

• 摘要

125.  Westerberg E, Molin C, Lindblad I, et al. Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: a pilot study. Muscle Nerve. 2017 Aug;56(2):207-14.

• 摘要

126.  Rahbek MA, Mikkelsen EE, Overgaard K, et al. Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training. Muscle Nerve. 2017 Oct;56(4):700-9.

• 摘要